{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:29:35Z","timestamp":1790936975428,"version":"4.1.0"},"reference-count":50,"publisher":"Spandidos Publications","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010]]},"DOI":"10.3892\/etm.2010.127","type":"journal-article","created":{"date-parts":[[2010,7,22]],"date-time":"2010-07-22T12:36:14Z","timestamp":1279802174000},"page":"739-746","source":"Crossref","is-referenced-by-count":50,"title":["Inhibition of tumor angiogenesis by oral etoposide"],"prefix":"10.3892","volume":"1","author":[{"given":"DIPAK","family":"PANIGRAHY","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ARJA","family":"KAIPAINEN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"CATHERINE E.","family":"BUTTERFIELD","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DEVINEY M.","family":"CHAPONIS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ANDREA M.","family":"LAFORME","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JUDAH","family":"FOLKMAN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MARK W.","family":"KIERAN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2010,7,21]]},"reference":[{"key":"key20180108131400_b1-etm-01-05-0739","first-page":"1878","article-title":"Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer","volume":"60","author":"Browder","year":"2000","journal-title":"Cancer Res"},{"key":"key20180108131400_b2-etm-01-05-0739","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1172\/JCI8829","article-title":"Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity","volume":"105","author":"Klement","year":"2000","journal-title":"J Clin Invest"},{"key":"key20180108131400_b3-etm-01-05-0739","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1172\/JCI9872","article-title":"Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice","volume":"105","author":"Hanahan","year":"2000","journal-title":"J Clin Invest"},{"key":"key20180108131400_b4-etm-01-05-0739","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nrc1369","article-title":"The anti-angiogenic basis of metronomic chemotherapy","volume":"4","author":"Kerbel","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"key20180108131400_b5-etm-01-05-0739","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrd2115","article-title":"Angiogenesis: an organizing principle for drug discovery?","volume":"6","author":"Folkman","year":"2007","journal-title":"Nat Rev Drug Discov"},{"key":"key20180108131400_b6-etm-01-05-0739","first-page":"2731","article-title":"Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water","volume":"62","author":"Man","year":"2002","journal-title":"Cancer Res"},{"key":"key20180108131400_b7-etm-01-05-0739","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1097\/01.mph.0000183863.10792.d4","article-title":"A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer","volume":"27","author":"Kieran","year":"2005","journal-title":"J Pediatr Hematol Oncol"},{"key":"key20180108131400_b8-etm-01-05-0739","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1002\/cncr.11775","article-title":"Antiangiogenetic therapy with pioglitazone, rofecoxib, and metronomic trofosfamide in patients with advanced malignant vascular tumors","volume":"98","author":"Vogt","year":"2003","journal-title":"Cancer"},{"key":"key20180108131400_b9-etm-01-05-0739","first-page":"308","article-title":"Combined biodifferentiating and antiangiogenic oral metronomic therapy is feasible and effective in relapsed solid tumors in children: single-center pilot study","volume":"29","author":"Sterba","year":"2006","journal-title":"Onkologie"},{"key":"key20180108131400_b10-etm-01-05-0739","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/1097-0142(19910101)67:1+<215::AID-CNCR2820671302>3.0.CO;2-D","article-title":"Etoposide. Current and future status","volume":"67","author":"Aisner","year":"1991","journal-title":"Cancer"},{"key":"key20180108131400_b11-etm-01-05-0739","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/00000421-199810000-00018","article-title":"Treatment of non-small cell lung cancer with prolonged oral etoposide","volume":"21","author":"Kakolyris","year":"1998","journal-title":"Am J Clin Oncol"},{"key":"key20180108131400_b12-etm-01-05-0739","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1200\/JCO.1996.14.6.1922","article-title":"Response of recurrent medulloblastoma to low-dose oral etoposide","volume":"14","author":"Ashley","year":"1996","journal-title":"J Clin Oncol"},{"key":"key20180108131400_b13-etm-01-05-0739","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/01.COC.0000020590.62677.E0","article-title":"Oral etoposide (VP16) in platinum-resistant epithelial ovarian cancer (EOC)","volume":"26","author":"Alici","year":"2003","journal-title":"Am J Clin Oncol"},{"key":"key20180108131400_b14-etm-01-05-0739","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1200\/JCO.1994.12.5.986","article-title":"Clinical activity of chronic oral etoposide in previously treated metastatic breast cancer","volume":"12","author":"Martin","year":"1994","journal-title":"J Clin Oncol"},{"key":"key20180108131400_b15-etm-01-05-0739","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/pbc.10393","article-title":"Oral etoposide for recurrent\/progressive sarcomas of childhood","volume":"42","author":"Kebudi","year":"2004","journal-title":"Pediatr Blood Cancer"},{"key":"key20180108131400_b16-etm-01-05-0739","first-page":"473","article-title":"VP-16-213 monotherapy for remission induction of small cell lung cancer: a randomized trial using three dosage schedules","volume":"62","author":"Cavalli","year":"1978","journal-title":"Cancer Treat Rep"},{"key":"key20180108131400_b17-etm-01-05-0739","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/BF00665790","article-title":"Second-line chemotherapy with long-term low-dose oral etoposide in patients with advanced breast cancer","volume":"34","author":"Bontenbal","year":"1995","journal-title":"Breast Cancer Res Treat"},{"key":"key20180108131400_b18-etm-01-05-0739","first-page":"132","article-title":"Tumor angiogenesis","volume-title":"Cancer Medicine","author":"Folkman","year":"2000","edition":"5th edition"},{"key":"key20180108131400_b19-etm-01-05-0739","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/S0923-1811(00)00089-X","article-title":"Treatment of murine angiosarcoma with etoposide, TNP-470 and prednisolone","volume":"24","author":"Ma","year":"2000","journal-title":"J Dermatol Sci"},{"key":"key20180108131400_b20-etm-01-05-0739","first-page":"1759","article-title":"Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy","volume":"24","author":"Drevs","year":"2004","journal-title":"Anticancer Res"},{"key":"key20180108131400_b21-etm-01-05-0739","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/0092-8674(94)90200-3","article-title":"Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma","volume":"79","author":"O'Reilly","year":"1994","journal-title":"Cell"},{"key":"key20180108131400_b22-etm-01-05-0739","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1172\/JCI0215634","article-title":"PPAR\u03b3 ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis","volume":"110","author":"Panigrahy","year":"2002","journal-title":"J Clin Invest"},{"key":"key20180108131400_b23-etm-01-05-0739","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s00432-004-0642-z","article-title":"Anti-angiogenic effects of SN38 (active metabolite of irinotecan): inhibition of hypoxia-inducible factor 1 alpha (HIF-1alpha)\/vascular endothelial growth factor (VEGF) expression of glioma and growth of endothelial cells","volume":"131","author":"Kamiyama","year":"2005","journal-title":"J Cancer Res Clin Oncol"},{"key":"key20180108131400_b24-etm-01-05-0739","doi-asserted-by":"crossref","first-page":"4368","DOI":"10.1200\/JCO.2002.10.088","article-title":"Vascular permeability factor\/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy","volume":"20","author":"Dvorak","year":"2002","journal-title":"J Clin Oncol"},{"key":"key20180108131400_b25-etm-01-05-0739","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.3748\/wjg.v10.i8.1191","article-title":"Adeno-associated virus mediated endostatin gene therapy in combination with topoisomerase inhibitor effectively controls liver tumor in mouse model","volume":"10","author":"Hong","year":"2004","journal-title":"World J Gastroenterol"},{"key":"key20180108131400_b26-etm-01-05-0739","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1089\/108497803770418355","article-title":"Sterically stabilized etoposide liposomes: evaluation of antimetastatic activity and its potentiation by combination with sterically stabilized pentoxifylline liposomes in mice","volume":"18","author":"Sant","year":"2003","journal-title":"Cancer Biother Radiopharm"},{"key":"key20180108131400_b27-etm-01-05-0739","first-page":"1306","article-title":"Antiangiogenic and antitumor activities of cyclooxgenase-2 inhibitors","volume":"60","author":"Masferrer","year":"2000","journal-title":"Cancer Res"},{"key":"key20180108131400_b28-etm-01-05-0739","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1126\/science.1125950","article-title":"Antiangiogenic therapy: a universal chemosensitization strategy for cancer?","volume":"312","author":"Kerbel","year":"2006","journal-title":"Science"},{"key":"key20180108131400_b29-etm-01-05-0739","doi-asserted-by":"crossref","first-page":"7045","DOI":"10.1158\/0008-5472.CAN-05-0765","article-title":"Low-dose metronomic combined with intermittent bolus-dose cyclophosphamide is an effective long-term chemotherapy treatment strategy","volume":"65","author":"Shaked","year":"2005","journal-title":"Cancer Res"},{"key":"key20180108131400_b30-etm-01-05-0739","first-page":"6938","article-title":"Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs","volume":"62","author":"Bocci","year":"2002","journal-title":"Cancer Res"},{"key":"key20180108131400_b31-etm-01-05-0739","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1158\/0008-5472.CAN-03-3126","article-title":"Thrombospondin-1 associated with tumor microenvironment contributes to low-dose cyclophosphamide-mediated endothelial cell apoptosis and tumor growth suppression","volume":"64","author":"Hamano","year":"2004","journal-title":"Cancer Res"},{"key":"key20180108131400_b32-etm-01-05-0739","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/(SICI)1096-911X(199707)29:1<28::AID-MPO5>3.0.CO;2-U","article-title":"Phase II study of daily oral etoposide in children with recurrent brain tumors and other solid tumors","volume":"29","author":"Needle","year":"1997","journal-title":"Med Pediatr Oncol"},{"key":"key20180108131400_b33-etm-01-05-0739","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0145-2126(97)00149-5","article-title":"Treatment with low-dose oral etoposide in patients with myelodysplastic syndromes","volume":"22","author":"Doll","year":"1998","journal-title":"Leuk Res"},{"issue":"Suppl 3","key":"key20180108131400_b34-etm-01-05-0739","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2165\/00003495-199958003-00008","article-title":"Extended-schedule oral etoposide in selected neoplasms and overview of administration and scheduling issues","volume":"58","author":"Hainsworth","year":"1999","journal-title":"Drugs"},{"key":"key20180108131400_b35-etm-01-05-0739","first-page":"1517","article-title":"Clinical pharmacology of chronic oral etoposide in patients with small cell and non-small cell lung cancer","volume":"1","author":"Zucchetti","year":"1995","journal-title":"Clin Cancer Res"},{"key":"key20180108131400_b36-etm-01-05-0739","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/0959-8049(95)00026-F","article-title":"Exposure and schedule dependency of etoposide in neuroblastoma and leukaemia cells in vitro","volume":"31A","author":"Lowis","year":"1995","journal-title":"Eur J Cancer"},{"key":"key20180108131400_b37-etm-01-05-0739","first-page":"715","article-title":"Schedule dependency of the antileukemic activity of the podophyllotoxin-derivative VP 16-213 (NSC-141540) in L1210 leukemia","volume":"81","author":"Dombernowsky","year":"1973","journal-title":"Acta Pathol Microbiol Scand [A]"},{"key":"key20180108131400_b38-etm-01-05-0739","first-page":"1331","article-title":"Antiangiogenic chemotherapeutic agents: characterization in comparison to their tumor growth inhibition in human renal cell carcinoma models","volume":"4","author":"Schirner","year":"1998","journal-title":"Clin Cancer Res"},{"key":"key20180108131400_b39-etm-01-05-0739","doi-asserted-by":"crossref","first-page":"4789","DOI":"10.1158\/0008-5472.CAN-05-4012","article-title":"Estradiol and tamoxifen regulate endostatin generation via matrix metalloproteinase activity in breast cancer in vivo","volume":"66","author":"Nilsson","year":"2006","journal-title":"Cancer Res"},{"key":"key20180108131400_b40-etm-01-05-0739","doi-asserted-by":"crossref","first-page":"13243","DOI":"10.1073\/pnas.202392199","article-title":"Divergent effects of new cyclooxygenase inhibitors on gastric ulcer healing: shifting the angiogenic balance","volume":"99","author":"Ma","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20180108131400_b41-etm-01-05-0739","first-page":"2339","article-title":"Imbalance in production between vascular endothelial growth factor and endostatin in patients with rheumatoid arthritis","volume":"27","author":"Nagashima","year":"2000","journal-title":"J Rheumatol"},{"key":"key20180108131400_b42-etm-01-05-0739","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1126\/science.1068327","article-title":"Effect of p53 status on tumor response to antiangiogenic therapy","volume":"295","author":"Yu","year":"2002","journal-title":"Science"},{"key":"key20180108131400_b43-etm-01-05-0739","doi-asserted-by":"crossref","first-page":"6678","DOI":"10.1158\/1078-0432.CCR-05-0621","article-title":"Metronomic low-dose chemotherapy boosts CD95-dependent antiangiogenic effect of the thrombospondin peptide ABT-510: a complementation anti-angiogenic strategy","volume":"11","author":"Yap","year":"2005","journal-title":"Clin Cancer Res"},{"key":"key20180108131400_b44-etm-01-05-0739","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.ccr.2007.02.025","article-title":"Synergy between PPARgamma ligands and platinum-based drugs in cancer","volume":"11","author":"Girnun","year":"2007","journal-title":"Cancer Cell"},{"key":"key20180108131400_b45-etm-01-05-0739","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1053\/ajot.2003.7","article-title":"Results of phase I\u2013II trial of concomitant hyperfractionated radiation and oral etoposide (VP-16) in patients with unresectable squamous cell carcinoma of the head and neck","volume":"24","author":"Khafif","year":"2003","journal-title":"Am J Otolaryngol"},{"key":"key20180108131400_b46-etm-01-05-0739","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/01.coc.0000135922.12198.e4","article-title":"Phase II trial of estramustine and etoposide in androgen-sensitive metastatic prostate carcinoma","volume":"27","author":"Vaishampayan","year":"2004","journal-title":"Am J Clin Oncol"},{"key":"key20180108131400_b47-etm-01-05-0739","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1093\/annonc\/mdi240","article-title":"Cyclophosphamidemethotrexate \u2018metronomic\u2019 chemotherapy for the palliative treatment of metastatic breast cancer. A comparative pharmacoeconomic evaluation","volume":"16","author":"Bocci","year":"2005","journal-title":"Ann Oncol"},{"key":"key20180108131400_b48-etm-01-05-0739","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1093\/jnci\/97.9.624","article-title":"When will the U.S. flinch at cancer drug prices?","volume":"97","author":"Vanchieri","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"key20180108131400_b49-etm-01-05-0739","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1158\/0008-5472.CAN-05-2598","article-title":"Low-dose metronomic daily cyclophosphamide and weekly tirapazamine: a well-tolerated combination regimen with enhanced efficacy that exploits tumor hypoxia","volume":"66","author":"Emmenegger","year":"2006","journal-title":"Cancer Res"},{"key":"key20180108131400_b50-etm-01-05-0739","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s000110300065","article-title":"Impact of topoisomerase II inhibition on cytokine and chemokine production","volume":"52","author":"Verdrengh","year":"2003","journal-title":"Inflamm Res"}],"container-title":["Experimental and Therapeutic Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/etm.2010.127\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,8]],"date-time":"2018-01-08T18:07:35Z","timestamp":1515434855000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/etm.2010.127"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010]]},"references-count":50,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2010,7,21]]},"published-print":{"date-parts":[[2010]]}},"alternative-id":["10.3892\/etm.2010.127"],"URL":"https:\/\/doi.org\/10.3892\/etm.2010.127","relation":{},"ISSN":["1792-0981","1792-1015"],"issn-type":[{"value":"1792-0981","type":"print"},{"value":"1792-1015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010]]}}}